- LGBT adults still lean overwhelmingly toward Democratic Party
- Lawmakers rattled by Syria genocide horrors, call on Obama to act
- African leader cancels trip to U.S. over Ebola outbreak; Obama still plans summit
- Sarah Palin’s online channel hits snag when Stephen Colbert buys similar URL
- SWAT spends seven hours in standoff with empty home
- U.S. troops told not to eat, drink in front of Muslims during Ramadan
- Iran’s Rouhani: Israel, Islamic State are ‘tumors derived from the same origin’
- Rep. Tim Murphy: GOP knew HealthCare.gov would be an ‘unmitigated disaster’
- Political speak: Planned Parenthood dumps ‘pro-choice’ for ‘women’s health’
- U.S. attorney warns Cuomo not to interfere with anti-corruption probes
Highly anticipated weight-loss pill wins approval
Question of the Day
The FDA initially rejected Vivus‘ drug in 2010 over concerns that it can cause birth defects if taken by pregnant women. The agency laid out a risk-management plan Tuesday specifically designed to minimize the chance of the women becoming pregnant while using the drug. It recommends that women of childbearing age test negative for pregnancy before starting the drug and take a monthly pregnancy test while taking it.
The agency also said patients with recent or unstable heart disease or stroke aren’t good candidates for the drug because its effect on heart rates in those patients is not known. Vivus has to do studies of the heart effects of Qsymia, the FDA said.
Analysts estimate the new pill could garner more than $1 billion in sales by 2016, though Mountain View, Calif.-based Vivus plans a slow rollout.
The pill will launch with a relatively small sales force of 150 representatives. Company executives say their initial marketing efforts will focus on obesity specialists, not general doctors.
“We’re going to have to grow our sales organization in order to support the primary care market,” Vivus President Peter Tam said in an interview with the Associated Press.
Rival Arena Pharmaceuticals Inc. of San Diego plans to start selling Belviq early next year. A third California drugmaker, Orexigen Therapeutics Inc., is still running clinical trials of its product, Contrave, and is working toward an FDA approval date in 2014.
TWT Video Picks
By Ted Cruz
Israel saves its enemies; Hamas endangers its friends
- Al Gore's climate-changers at EPA hearings foiled by cool temperatures
- Geraldo Rivera: Matt Drudge 'doing his best to stir up a civil war'
- Chicken pox outbreak puts illegal immigrant facility on lockdown
- GOP report sees ties between rich donors, green 'nonprofits'
- House votes to sue President Obama over claims of presidential power
- NAPOLITANO: Is the president incompetent or lawless?
- Lois Lerner hated conservatives, new emails show
- Israel surprised by Hamas tunnel network
- CRUZ: A tale of two hospitals: One in Israel, one in Gaza
- EDITORIAL: The real Lois Lerner exposed in newly released emails
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world